AngioDynamics Receives 510-k- Clearance of MORPHEUS CT PICC
PICCs are used for short- and long-term peripheral access to the central venous system in order to administer chemotherapy or other medications that require significant dilution in the blood to avoid blood vessel damage. The MORPHEUS CT PICC is constructed of a biocompatible and durable material called Durathane, which offers increased stiffness on the proximal end for ease of placement, a softer distal end for patient comfort, and simplified site care. The indications for use with CT injectors will allow physicians to use the existing PICC for both medications and CT imaging, avoiding the need for an additional access site.
Commenting for AngioDynamics, Don Geer, Director, Vascular Access Products, said, "A key feature of the MORPHEUS CT PICC is its dual capability for CT imaging and therapeutic delivery of medications. This benefits patients and physicians by reducing the number of times a physician must access a vein and can result in cost savings to the health care facility. This innovative approach to PICCs is another example of AngioDynamics' commitment to improving patient care."
For additional information on the MORPHEUS CT PICC, contact Don Geer at 1-800-772-6446, ext. 167, Email: dgeer@angiodynamics.com or visit the AngioDynamics web site at www.angiodynamics.com.
About AngioDynamics
AngioDynamics, Inc. (www.angiodynamics.com) designs, develops, manufactures and markets innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease. It offers a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. AngioDynamics' diversified product line includes angiographic catheters, hemodialysis catheters, PTA dilation catheters, thrombolytic products, image-guided vascular access products, endovascular laser venous system products, as well as drainage products. AngioDynamics is a majority-owned subsidiary of E-Z-EM, Inc. (AMEX:EZM), a leading manufacturer of contrast agents for gastrointestinal radiology.
The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, market acceptance and future sales of the MORPHEUS CT Injectable PICC, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, including alternative procedures which continue to replace traditional fluoroscopic procedures, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended February 28, 2004, as well as its Annual Report on Form 10-K for the year ended May 31, 2003, may affect the actual results achieved by the Company.
CONTACT: AngioDynamics, Inc.
Lisa Donegan, 800-772-6446 x370
www.angiodynamics.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
Bruce Voss, 310-691-7100
bvoss@lhai.com
SOURCE: AngioDynamics, Inc.